- Home
- RERE vs EBS Comparison
RERE vs EBS Comparison
Compare RERE & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- EBS
- Stock Information
- Founded
- RERE 2011
- EBS 1998
- Country
- RERE China
- EBS United States
- Employees
- RERE N/A
- EBS N/A
- Industry
- RERE Other Specialty Stores
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- EBS Health Care
- Exchange
- RERE Nasdaq
- EBS Nasdaq
- Market Cap
- RERE 444.1M
- EBS 393.9M
- IPO Year
- RERE 2021
- EBS 2006
- Fundamental
- Price
- RERE $2.58
- EBS $6.32
- Analyst Decision
- RERE
- EBS Strong Buy
- Analyst Count
- RERE 0
- EBS 3
- Target Price
- RERE N/A
- EBS $14.33
- AVG Volume (30 Days)
- RERE 847.7K
- EBS 1.4M
- Earning Date
- RERE 05-20-2025
- EBS 05-07-2025
- Dividend Yield
- RERE N/A
- EBS N/A
- EPS Growth
- RERE N/A
- EBS N/A
- EPS
- RERE 0.07
- EBS N/A
- Revenue
- RERE $2,388,301,386.00
- EBS $965,400,000.00
- Revenue This Year
- RERE $29.57
- EBS N/A
- Revenue Next Year
- RERE $24.43
- EBS $16.07
- P/E Ratio
- RERE $35.61
- EBS N/A
- Revenue Growth
- RERE 26.09
- EBS N/A
- 52 Week Low
- RERE $2.00
- EBS $4.02
- 52 Week High
- RERE $3.70
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- RERE 48.53
- EBS 55.78
- Support Level
- RERE $2.45
- EBS $6.13
- Resistance Level
- RERE $2.95
- EBS $6.68
- Average True Range (ATR)
- RERE 0.15
- EBS 0.38
- MACD
- RERE -0.01
- EBS 0.01
- Stochastic Oscillator
- RERE 25.00
- EBS 59.06
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.